[7] Vidarsson, et al. frontiers in immunology, 2014 Oct 20;5:520 [8] Liu R, et al. Antibodies (Basel). 2020 Nov 17;9(4):64. [9] Peng Q, et al. Nat Commun. 2020 Sep 24;11(1):4835. [10] Wang J...
1、Drew M. Pardoll. The blockade of immune checkpoints in cancer immunotherapy[J]. Nat Rev Cancer. 2012 Mar 22;12(4):252-64. 2、Annika De Sousa Linhares, Claire Battin, Sabrina Jutz, et al. Therapeutic PD-L1 antibodies are more effective than PD-1 a...
[2].Annika De Sousa Linhares, Claire Battin, Sabrina Jutz, et al. Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling[J]. Sci Rep. 2019 Aug 7;9(1):11472. [3].Jifeng Yu, Yongping Song, Wenzhi Tian. How to select IgG subclasses i...
参考文献 [1] Kim C. Ohaegbulam, et al. Human cancer immunotHERapy with antibodies to the PD-1 and PD-L1 pathway. Trends in Molecular Medicine, 2015. [2] Mayoux, M., et al. "Dendritic cells dictate responses to PD-L1 blockade cancer immunotHERapy." Science Translational Medicine 12.534...
参考文献：Yin Z, Yu M, Ma T, Zhang C, Huang S, Karimzadeh MR, Momtazi-Borojeni AA, Chen S. Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1. J Immunother Cancer. 2021 Jan;9(1):e001698. doi: ...
2、Annika De Sousa Linhares, Claire Battin, Sabrina Jutz, et al. Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling[J]. Sci Rep. 2019 Aug 7;9(1):11472. 3、Jifeng Yu, Yongping Song, Wenzhi Tian. How to select IgG subclasses in de...
Molecular mechanism of PD-1/PD-L1 blockadevia anti-PD-L1 antibodies atezolizumab and durvalumab Safety profiles of anti-CTLA‑4 and anti‑PD‑1 antibodies alone and in combination Tcell co-stimulatory receptor CD28 is a primary target for PD-1–mediatedinhibition Rescueof exhausted CD8 T ce...
5.https://www.antibodysociety.org/resources/approved-antibodies/ 附表：欧盟或美国批准的抗体治疗剂或经过监管审查的抗体 参考资料 1. Asher Mullard. FDA approves 100th monoclonal antibody product. Nature Reviews Drug Discovery. 2021，05 May 声明：本文仅代表作者个人观点，不代表医药魔方观点和立场，不构成...
host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease requiring stimulation of immune responses...
5.Kitagawa S, et al. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review. Thorac Cancer. 2020 Jul;11(7):1927-1933. ...